AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03257813 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PRO-122
Description: 1 drop every 12 hours for 30 days of alternating treatment with 30 days
Study NCT03257813 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Krytantek Ofteno®
Description: 1 drop every 12 hours for 30 days of alternating treatment with 30 days
Study NCT02562391 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical ablation of the left atrium (PVI+Box lesions)
Study NCT02562391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgical ablation of the left atrium (PVI+Box lesions) and left atrial appendage cutting
Study NCT01305291 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT01305291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: digestion-resistant maltodextrin
Study NCT01305291 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: digestion-resistant maltodextrin
Study NCT02683811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diario della Salute (DDS-2)
Description: The updated version of Diario della Salute program (DDS-2) includes: 1) teachers' manual, 2) a booklet for teens telling the story of four same-age students (e.g. experimenting with risky behaviours, conflicting feelings and thoughts, need for independence and control, etc.), 3) a booklet for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflicts, parental control and supervision, family communication, etc.).
Study NCT02602743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanyl
Description: 0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
Study NCT02602743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started.
Study NCT02602743 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: 2 mg/kg ketamine will be administered for induction in 1 minute.
Study NCT02602743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 2 mg/kg ketamine will be administered for induction in 1 minute.
Study NCT00801983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alternative Keyboard
Description: Subjects use either a typical or alternative keyboard
Study NCT01424540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2336805 150mg
Description: Single Dose
Study NCT01424540 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single Dose
Study NCT02910388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LLETZ with colposcopy
Description: Loop procedure using a colposcope in order to see and remove the abnormal cervical tissue
Study NCT02910388 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LLETZ without colposcopy
Description: Loop procedure without using a colposcope
Study NCT00676234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epoetinum
Description: Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
Study NCT03522467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRCP001
Description: MRCP001 is a formulated whole-plant cannabis oil extract, that may help manage poorly controlled chronic pain.
Study NCT03103295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3D-Tissue Engineered Bone Equivalent
Description: Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent
Study NCT04617652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: Patients will receive 1 gm of magnesium in 10 ml over 5 minutes then infusion of 1 gm in 50 ml over one hour.
Study NCT04617652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients will receive 10 ml of saline, then infusion of 50 ml of normal saline over one hour.
Study NCT04033042 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prototype 0.5
Description: Subjects will perform daily measurements on the IMD (Prototype 0.5) for 41 days.
Study NCT02765438 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BOBO
Description: Each subject will play four games with the BOBO system.
Study NCT01883908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture with Seirin® needles
Description: Participants will be randomized to receive either usual medical care or acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
Study NCT01883908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual medical care
Description: usual medical care such as viscous Lidocaine for relief of pain
Study NCT01883908 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual medical care
Description: usual medical care such as viscous Lidocaine for relief of pain
Study NCT02778958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: iv paracetamol flakon, 1 gram infusion at 30 min;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
Study NCT02778958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: iv ibuprofen flakon, 800 mg;~iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)
Study NCT04567407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilateral erector spinae blocks using ropivacaine
Description: Bilateral chest wall nerve blocks using ropivacaine.
Study NCT02342119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Talking About Living Kidney Donation
Description: TALK participants receive a culturally sensitive educational booklet and video. A study interventionist encourages participants to share the materials with their family members or friends. Materials provide information to encourage patient and families shared and informed consideration of LDKT, including: 1) information about eligibility for LDKT, 2) the clinical evaluation required for LDKT, 3) the donor selection process, 4) surgical procedures for transplantation and donation, 5), and concerns brought forth about these factors, identified through structured group interviews.
Study NCT02342119 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kidney Transplant Fast Track
Description: KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
Study NCT02342119 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kidney Transplant Fast Track
Description: KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
Study NCT04153435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Chloride
Description: Calcium chloride 5 mmol
Study NCT04153435 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride 0.9%
Description: Placebo
Study NCT00864786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF03635659
Description: Inhaled doses of 200 mcgQD
Study NCT00864786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF03635659
Description: Inhaled doses of 600 mcg QD
Study NCT00864786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF03635659
Description: Inhaled doses of 1000 mcg QD
Study NCT00864786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF03635659
Description: Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
Study NCT04052971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABN401- Escalation Phase
Description: Dose administration: Escalation Phase The regular dose levels of ABN401 will range from 50 mg to 1800 mg QD daily for 21 days.
Study NCT04052971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABN401- Expansion Phase
Description: Dose administration: Expansion Phase The expansion phase of the study will use the dose and schedule determined to be most appropriate in the dose escalation portion of the study. This may be the MTD and/or the RP2D and will consist of cohorts of NSCLC patients with c-MET dysregulation.~Patients will receive ABN401 800 mg, administered orally once daily for 21 days until disease progression, unacceptable toxicity, or patient withdrawal.
Study NCT01885806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Stimulator Magstim Rapid 2
Description: All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freqüency: 10 Hz Intensity: 90% limiar motor Session duration: 16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex
Study NCT01885806 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Magnetic Stimulator
Description: This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.~Total of session: 10
Study NCT00867191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 tablet daily, per os., 15 days
Study NCT00867191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: Desloratadine, one 5 mg tablet daily, per os, 15 days
Study NCT01259258 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without dye varicocelectomy
Description: 40 controls in whom no mapping technique was adopted in the period between
Study NCT03279952 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: CNS Stimulant
Description: Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
Study NCT01276626 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum
Description: Powder containing Bifidobacterium longum in maltodextrin.
Study NCT01276626 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Powder containing only maltodextrin
Study NCT03047135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until the patient completes the study, withdraws from the study or closure of the study.
Study NCT00918619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sangustop
Description: Application of Sangustop haemostatic agent on resection area
Study NCT03763175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYN-010 21 mg
Description: 21 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
Study NCT03763175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SYN-010 42 mg
Description: 42 mg lovastatin will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
Study NCT03763175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo will be administered to patients diagnosed with IBS-C to evaluate whether the medication and dose is effective in increasing frequency of completely spontaneous bowel movements. The secondary objectives of the study are to assess the role of lovastatin lactone in increasing overall stool frequency and reducing abdominal pain severity, bloating severity, and rescue medication use. Additional endpoints include improvement in reported adequate relief and the effect of the study drug in lowering exhaled methane levels.
Study NCT02846480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: Pre-surgical Physical Therapy: physical therapy aimed to correct the posture, to the awareness and the strengthening of the pelvic floor muscles.~Post-surgical Physical Therapy: checking the correct contraction of the pelvic floor muscles and hypopressive exercises.
Study NCT02846480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgical treatment
Description: Surgical correction of POP.
Study NCT02846480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavior therapy
Description: At hospital discharge, patients will receive a fact sheet on the sanitary and behavioral measures recommended for the prevention of POP and urinary incontinence (proper weight, prevent constipation, avoid weight bearing and cough and high impact exercise).
Study NCT03368937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim X2 with Control-IQ Technology
Description: Subjects will wear the Tandem t:slim X2 with Control-IQ Technology during a 36-48 hour hotel admission.
Study NCT01271452 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A
Description: 20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
Study NCT00918619 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tachosil
Description: Application of Tachosil fibrin sealant on resection area
Study NCT01271452 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A
Description: 30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
Study NCT03614546 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy (SBRT)
Study NCT03614546 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity-modulated Radiation Therapy (IMRT)
Study NCT01882465 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: etafilcon A
Description: Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
Study NCT01882465 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: 2-HEMA, EGDMA Non-ionic
Description: Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
Study NCT01882465 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: hefilcon A
Description: Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
Study NCT00153660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib(drug)
Description: Celecoxib 100 mg bd
Study NCT00153660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen(drug)
Description: Naproxen 500 mg bd
Study NCT01736917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant
Description: Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis
Study NCT01736917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8
Study NCT01736917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5HT3
Description: Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.
Study NCT01392157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: copper-releasing intrauterine device
Description: 100 women received a 380 mm2 of copper releasing intrauterine device
Study NCT01392157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ENG-releasing implant
Description: 60 mcg/day releasing etonogestrel implant
Study NCT01392157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LNG-releasing intrauterine system
Description: a LNG-IUS releasing 20 mcd/day of LNG
Study NCT03614546 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hepatectomy
Description: Hepatectomy
Study NCT03614546 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: transarterial chemoembolization (TACE)
Study NCT01392157 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LNG-IUS
Description: 100 women will receive an LNG-IUS
Study NCT03686891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin prick tests with four native legumes
Description: Skin prick tests with four native legumes
Study NCT02947516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous liver biopsy
Description: Participants will undergo percutaneous liver biopsy per standard protocol.
Study NCT00757770 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Two oral doses.
Study NCT00757770 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Two oral doses; The placebo consist of all components of the study vaccine i.e. excipients and buffer, but no RV particles.
Study NCT02537704 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Lifestyle Balance Program
Study NCT01228916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation and Secondhand Smoke Reduction
Description: Awareness raising and resources for cessation and secondhand smoke reduction
Study NCT01429792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: standard treatment, subcutaneously weekly
Study NCT01429792 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin [Copegus]
Description: standard treatment, orally daily
Study NCT04433429 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Liposcudil Plus
Study NCT02599935 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hypercaloric beverages
Description: Nutritional supplement: Hypercaloric beverages
Study NCT02599935 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: No other than standard treatment
Study NCT02599935 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational structured counseling
Description: Nutritional counseling leaded to patient and caregivers
Study NCT01948648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colesevelam
Description: Drug is in powder form, each packet contains 3.75g of colesevelam hydrochloride. Participant will mixed it with water and have 1 packet per day during the treatment session.
Study NCT01948648 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fish Oil
Description: In softgel form, contains 660mg EPA and 330mg DHA. Participant consume 1 softgel per day during treatment session.
Study NCT01948648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combination of fish oil and colesevelam
Description: combination of both colesevelam and fish oil. Participant will consume 1 packet and 1 softgel per day during treatment session.
Study NCT04820439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)
Description: A single intravenous infusion of HS627 420mg
Study NCT04820439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta ®
Description: A single intravenous infusion of Perjeta ®420mg
Study NCT01043263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EN3324 (axomadol)
Description: twice daily dosing
Study NCT01043263 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: twice daily dosing
Study NCT00476255 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard Care (ESC)
Description: Reading material